Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jerry R Colca

Showing results (31-40 of 48) with videos related to

Pageof 5
Sort By:
Journal of Hepatology|July 2, 2020
Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trialsBeth A Davison, Stephen A Harrison, Gad Cotter, et al.
Hepatology (Baltimore, Md.)|December 28, 2016
Targeting the mitochondrial pyruvate carrier attenuates fibrosis in a mouse model of nonalcoholic steatohepatitisKyle S McCommis, Wesley T Hodges, Elizabeth M Brunt, et al.
Molecular Cell|May 15, 2007
The site of action of oxazolidinone antibiotics in living bacteria and in human mitochondriaKaren L Leach, Steven M Swaney, Jerry R Colca, et al.
The Journal of Biological Chemistry|May 25, 2012
Insulin resistance and metabolic derangements in obese mice are ameliorated by a novel peroxisome proliferator-activated receptor γ-sparing thiazolidinedioneZhouji Chen, Patrick A Vigueira, Kari T Chambers, et al.
Journal of Hepatology|November 8, 2019
Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb studyStephen A Harrison, Naim Alkhouri, Beth A Davison, et al.
Free Neuropathology|February 28, 2022
Inhibiting the mitochondrial pyruvate carrier does not ameliorate synucleinopathy in the absence of inflammation or metabolic deficitsWouter Peelaerts, Liza Bergkvist, Sonia George, et al.
Experimental Physiology|June 10, 2017
The beneficial metabolic effects of insulin sensitizers are not attenuated by mitochondrial pyruvate carrier 2 hypomorphismPatrick A Vigueira, Kyle S McCommis, Wesley T Hodges, et al.
Bioorganic & Medicinal Chemistry|November 16, 2018
PPARγ-sparing thiazolidinediones as insulin sensitizers. Design, synthesis and selection of compounds for clinical developmentSteven P Tanis, Jerry R Colca, Timothy T Parker, et al.
Diabetes & Vascular Disease Research|July 27, 2007
Thiazolidinediones inhibit the progression of established hypertension in the Dahl salt-sensitive ratCharles W Bolten, Maria A Payne, William G McDonald, et al.
Molecular Metabolism|February 21, 2023
Mitochondrial pyruvate carrier inhibition initiates metabolic crosstalk to stimulate branched chain amino acid catabolismDaniel Ferguson, Sophie J Eichler, Nicole K H Yiew, et al.
Pageof 5

Showing results (31-40 of 48) with videos related to

Sort By:
Pageof 5
Journal of Hepatology|July 2, 2020
Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trialsBeth A Davison, Stephen A Harrison, Gad Cotter, et al.
Hepatology (Baltimore, Md.)|December 28, 2016
Targeting the mitochondrial pyruvate carrier attenuates fibrosis in a mouse model of nonalcoholic steatohepatitisKyle S McCommis, Wesley T Hodges, Elizabeth M Brunt, et al.
Molecular Cell|May 15, 2007
The site of action of oxazolidinone antibiotics in living bacteria and in human mitochondriaKaren L Leach, Steven M Swaney, Jerry R Colca, et al.
The Journal of Biological Chemistry|May 25, 2012
Insulin resistance and metabolic derangements in obese mice are ameliorated by a novel peroxisome proliferator-activated receptor γ-sparing thiazolidinedioneZhouji Chen, Patrick A Vigueira, Kari T Chambers, et al.
Journal of Hepatology|November 8, 2019
Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb studyStephen A Harrison, Naim Alkhouri, Beth A Davison, et al.
Free Neuropathology|February 28, 2022
Inhibiting the mitochondrial pyruvate carrier does not ameliorate synucleinopathy in the absence of inflammation or metabolic deficitsWouter Peelaerts, Liza Bergkvist, Sonia George, et al.
Experimental Physiology|June 10, 2017
The beneficial metabolic effects of insulin sensitizers are not attenuated by mitochondrial pyruvate carrier 2 hypomorphismPatrick A Vigueira, Kyle S McCommis, Wesley T Hodges, et al.
Bioorganic & Medicinal Chemistry|November 16, 2018
PPARγ-sparing thiazolidinediones as insulin sensitizers. Design, synthesis and selection of compounds for clinical developmentSteven P Tanis, Jerry R Colca, Timothy T Parker, et al.
Diabetes & Vascular Disease Research|July 27, 2007
Thiazolidinediones inhibit the progression of established hypertension in the Dahl salt-sensitive ratCharles W Bolten, Maria A Payne, William G McDonald, et al.
Molecular Metabolism|February 21, 2023
Mitochondrial pyruvate carrier inhibition initiates metabolic crosstalk to stimulate branched chain amino acid catabolismDaniel Ferguson, Sophie J Eichler, Nicole K H Yiew, et al.
Pageof 5